Form 4: Cyclo Therapeutics Director Francis Patrick Ostronic Reports Acquisition of Common Stock

Director Francis Patrick Ostronic acquired 70,329 shares of Cyclo Therapeutics common stock in lieu of cash compensation.

Summary

• On February 27, 2025, Francis Patrick Ostronic, a director of Cyclo Therapeutics, Inc., acquired 70,329 shares of common stock.
• The shares were received in lieu of cash compensation under the company's non-employee director compensation policy.
• This grant reflects director compensation for the fourth quarter of 2024 and from January 1, 2025 through March 25, 2025.
• The number of shares was calculated based on a closing price of $0.77 per share on February 26, 2025.
• Following the transaction, Ostronic directly owns 419,100 shares of Cyclo Therapeutics common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard transaction disclosure. The director taking stock instead of cash is a mildly positive signal.

Positives

• A director's decision to take compensation in stock aligns their interests with shareholders.
• The director now owns 419,100 shares.

Industry Context

This is a routine disclosure of a director's stock ownership change, which is common in publicly traded companies. It reflects part of the director's compensation package.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment as it aligns the director's interests with those of the shareholders.

Key Dates